UNSPSC 51402101: Chlormezanone

This classification denotes an anxiolytic with the molecular formula C11H12ClNO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GP568V9G19, chemically known as 4h-1,3-thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide but generally known as chlormezanone, which bears US NIH Compound Identifier 2717. European Medicines Agency schedules Chlormezanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06187MIG.

UNSPSC 51402101 Chlormezanone, a Commodity code, does not align with the state and local procurement activity recently posted under this classification. The three most recent opportunities tagged to this code solicited naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are chlormezanone-specific pharmaceutical procurement. The code appears to show little relevant recent activity, and the mismatch suggests that state and local issuing bodies may be incorrectly classifying pharmaceutical and health supply solicitations under this narrowly defined commodity code rather than broader pharmaceutical-family classifications.

The opportunities that do appear under this code reflect a broader pattern of state and local health procurement: Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems; the Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. Activity spans state health and human services departments, county health jurisdictions, and cooperative purchasing entities. Without a critical mass of chlormezanone-specific solicitations, this code presents minimal opportunity for vendors unless they are actively tracking pharmaceutical miscoding patterns or pursuing broadly defined health-supply contracts where misclassification occurs.